| B31 | OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection | E-poster | ART in acute infection |
| B32 | Integrase strand transfer inhibitor (INSTI) use and cancer incidence | E-poster | ART in first- and second-line therapies |
| B32 | Antiretroviral therapy for HIV controllers: indications and outcomes in the French ANRS-CO21 CODEX cohort | E-poster | ART in first- and second-line therapies |
| B32 | Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine? | E-poster | ART in first- and second-line therapies |
| B32 | High rates of viral suppression sixteen weeks after transition from EFV- to DTG-based ART regardless of viral load at transition: the DO-REAL cohort study in Lesotho | E-poster | ART in first- and second-line therapies |
| B32 | The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trial | E-poster | ART in first- and second-line therapies |
| B32 | Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: week 48 analysis from the randomized controlled phase 3 TALENT study | E-poster | ART in first- and second-line therapies |
| B32 | Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirine | E-poster | ART in first- and second-line therapies |
| B32 | Achievement of undetectable HIV-1 RNA in the B/F/TAF treatment-naïve clinical trials | E-poster | ART in first- and second-line therapies |
| B32 | Long-term analysis of B/F/TAF in treatment-naïve adults living with HIV through four years of follow-up | E-poster | ART in first- and second-line therapies |